2,5-Dimethoxy-4-trifluoromethylamphetamine (DOTFM) is the alpha-methylated analogue of 2C-TFM, a psychedelic drug of the phenethylamine and amphetamine chemical classes. 2,5-Dimethoxy-4-trifluoromethylamphetamine acts as an nanomolar agonist at the 5HT2A and 5HT2C receptors and possess hallucinogenic effects in humans.

CP-809101 is a potent, functionally selective 5-HT(2C) agonist that displays approximately 100% efficacy in vitro. CP-809101 has a pharmacological profile similar to that of the atypical antipsychotics with low extrapyramidal symptom liability. CP-809101 was active in novel object recognition, an animal model of cognitive function. It had promising results in animal models of obesity and psychosis.

SB-228357 was originally developed by scientists at Smith Kline Beecham (now merged with Glaxo Welcome to form GlaxoSmithKline). SB-228357 was identified as an antagonist of the serotonin receptors 5-HT2a/b/c with the highest affinity exhibited towards the 5-HT2C receptor. SB-228357 was identified for preclinical development as a treatment for depression, anxiety, and cataplexy but has not progressed beyond animal trials.